Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors Abstract #193
Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.
Aim(s): Ma2 is a new SI-NET biomarker. The goal is to evaluate whether anti-Ma2 detection in the blood is useful for clinical patient management.
Materials and methods: A novel indirect enzyme-linked immunosorbent assay (ELISA) was set up to detect Ma2 autoantibodies in blood. One-hundred and ninety blood samples from patients with SI-NET, typical and atypical lung carcinoids, different stage of disease, were used. Immunohistochemistry, Western blot, Sequential Immunoprecipitation and Immuno-Dot-blot analyses were used in the study.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Associate Profes Valeria Giandomenico
Authors: Cui T, Hurtig M, Li S C, Veronesi G, Essaghir A, Demoulin J B, Pelosi G, Alimohammadi M, Öberg K, Giandomenico V
To read results and conclusion, please login ...
Further abstracts you may be interested in
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: PhD Valeria Giandomenico
#672 Affinity Proteomic Plasma Analysis of Human Well-Differentiated Small Intestinal Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get diagnosis at the stage of metastasis and there is a lack of curative treatments.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Assoc. Prof, PhD Valeria Giandomenico
#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Tao Cui
Introduction: SI-NETs are often diagnosed late, which limits curative treatment options.
Conference: 13th Annual ENETS conference (2016)
Presenting Author: Kosmas Daskalakis
#583 Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get late diagnosis. We reported olfactory receptor 51E1 (OR51E1) as a SI-NET-mRNA marker.
Presenting Author: Mr TAO CUI